Escherichia coli as Next Generation Probiotics
Background E. coli and Diseases Products FAQs Resources
Creative Biolabs is a leading service provider that focuses on live biotherapeutics drug discovery services. We are committed and proud to be part of this rewarding challenge by offering its support to the novel next-generation probiotics (NGPs) development services and pre-clinical drug discovery for our clients. We are proud to partner with you on the journey of bringing novel Escherichia coli (E. coli)-based live biotherapeutics drugs to disease therapy in the clinic.
Introduction to Escherichia coli
E. coli, a key member of family Enterobacteriaceae, is a gram-negative bacterium with a length of 2.0 μm and a diameter of 0.20-1.1 μm that can be found in the most intestines. E. coli is a type of facultative anaerobe that can survive both aerobic and anaerobic conditions. In general, E. coli can produce adenosine triphosphate (ATP) through aerobic respiration in a case with oxygen, but converts to fermentation or anaerobic respiration in the absence of oxygen. Up to now, a wide variety of E. coli strains, including E. coli E22, E. coli UMN026, E. coli SE15, E. coli F11, and E. coli BL21-DE3, have been isolated from different human samples. Several E. coli strains are associated with food poisoning and are the main cause of diarrhea, urinary tract infections, pneumonia, respiratory diseases, as well as other disorders. However, most E. coli strains are harmless and can be considered as probiotic candidates and used for treating various human diseases.
E. coli for Diseases
Currently, the E. coli-based study in disease models plays an important role in developing a new group of live biotherapeutics drugs for treating a range of diseases. In the last few decades, many intense research attempts have been made to develop effective E. coli-based NGPs. As a result, Creative Biolabs provides a wide spectrum of E. coli- targeted NGPs discovery services for the treatment of many human diseases, including but not limited to:
|
Diseases
|
Functions of E. coli
|
|
Inflammatory Bowel Disease
|
Inflammatory bowel disease (IBD) is a group of autoimmune diseases that can cause long-term chronic inflammation in the intestine. Many studies have indicated that probiotic E. coli Nissle 1917 strain can provide enhanced protective effects on mice models, suggesting its promising role as a perfect NPG candidate and applied in the IBD treatment. Also, recent reports have shown that some E. coli strains have the characteristics of protective immune regulation and intestinal flora regulation.
|
|
Ulcerative Colitis
|
Ulcerative colitis (UC) is a common chronic relapsing disease that can lead to a continuous inflammation of the colon. Nowadays, the E. coli Nissle 1917 strain has shown health impacts on the host. Therefore, a large number of E. coli Nissle 1917 strain-based NGPs have been generated for treating patients suffering from UC. The data collected from clinical trials have proven that these NGPs are safe and effective in the prevention of relapses in UC patients. They can be regarded as an alternative to conventional drugs, such as mesalazine, for the UC treatment.
|
|
Colorectal Cancer
|
In recent years, new research has illustrated that some E. coli strains can be used for the generation of new therapies for human colorectal cancer (CRC). E. coli can induce strong immune and anti-inflammatory responses in the gut through macrophages or dendritic cells (DCs). Moreover, the clinical data have suggested that E. coli based NGPs are also effective in the management of drug side-effects and other complications.
|
Fig.1 Structure and mechanisms of action of Escherichia coli Nissle 1917 in disease treatment.1
As an expert in the field of drug discovery, Creative Biolabs is helping our customers with new live biotherapeutics drug discovery services targeting different disease types. Based on our deep analytical capabilities and vast experience in E. coli studies, our client-focused, the integrated team will anticipate challenges, overcome difficulties, and provide custom preclinical studies with numerous assays. We guarantee the finest results for our customers all over the world. For more information, please feel free to contact us or send us an inquiry.
Related Products
FAQs
What is the role of E. coli in next-generation probiotics?
E. coli, a bacterium commonly found in the human gut, is being explored for its potential as a next-generation probiotic due to its ability to modulate gut microbiota, enhance barrier function, and stimulate the immune system. Research into specific non-pathogenic strains has shown promising results for their use in promoting gastrointestinal health and preventing infections.
How does Creative Biolabs ensure the quality of its E. coli probiotic strains?
Creative Biolabs employs state-of-the-art genomic and phenotypic characterization techniques to ensure the highest quality of its E. coli probiotic strains. Each strain undergoes rigorous screening for safety, efficacy, and stability, adhering to stringent quality control standards. This comprehensive evaluation guarantees that only probiotic strains with proven benefits and no pathogenic potential are developed and provided for research purposes.
What support does Creative Biolabs offer for E. coli probiotic product development?
Creative Biolabs provides end-to-end support for E. coli probiotic product development, encompassing strain selection, formulation design, regulatory guidance, and scalability assessment. With expertise in microbiological research and bioprocessing, Creative Biolabs assists researchers and companies in developing probiotic products tailored to specific health targets, ensuring that every step from concept to final product is meticulously managed.
Can Creative Biolabs customize E. coli strains for specific research needs?
Yes, Creative Biolabs offers customization services for E. coli strains to meet specific research requirements. Leveraging advanced genetic engineering techniques, Creative Biolabs can modify E. coli strains to express desired traits, enhance probiotic efficacy, or target specific gastrointestinal conditions. This bespoke service allows researchers to explore the therapeutic potential of E. coli probiotics with strains precisely tailored to their study objectives.
Resources
Reference
-
Scaldaferri, F., et al. Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. World J Gastroenterol. 2016, 22(24): 5505-5511.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
